 |
|
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Jihyun An, Joo Hyun Sohn
Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online 2022 Dec 20 DOI: https://doi.org/10.3350/cmh.2022.0437
|
|
Citations to this article as recorded by
 NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials
Tripti Khare, Karina Liu, Lindiwe Oslee Chilambe, Sharad Khare
International Journal of Molecular Sciences.2025; 26(1): 306. CrossRef Hypoxia-inducible factor-1α inhibitor promotes non-alcoholic steatohepatitis development and increases hepatocellular lipid accumulation via TSKU upregulation
Renli Zeng, Yuxin Wang, Jielu Wen, Zhipeng Cen, Tengyao Wang, Meng Duan, Xiuyi Huang, Zhengde Zhao, Zhongyu Zhang, Chuan Yang, Sifan Chen
Archives of Biochemistry and Biophysics.2025; : 110313. CrossRef Albumin-fused thioredoxin ameliorates high-fat diet-induced non-alcoholic steatohepatitis
Ryota Murata, Hiroshi Watanabe, Ryotaro Iwakiri, Mayuko Chikamatsu, Takao Satoh, Isamu Noguchi, Kengo Yasuda, Ayano Nishinoiri, Takuma Yoshitake, Hiroto Nosaki, Hitoshi Maeda, Toru Maruyama
Heliyon.2024; 10(3): e25485. CrossRef Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
Sudha S. Shankar, Samuel J. Daniels, Darren Robertson, Janeli Sarv, José Sánchez, Debra Carter, Lutz Jermutus, Benjamin Challis, Arun J. Sanyal
Clinical Gastroenterology and Hepatology.2024; 22(9): 1847. CrossRef Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
American Journal of Gastroenterology.2024;[Epub] CrossRef Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease
Mohamed N. Abdelnabi, Ghada S. Hassan, Naglaa H. Shoukry
Frontiers in Immunology.2024;[Epub] CrossRef An economically viable stable isotope-enhanced multiple reaction monitoring method for total fatty acid analysis in a mouse model of non-alcoholic fatty liver disease
Zijia Zhang, Yawen Liu, Gaohan Li, Xiaoling Chen, Min Lei, Yang Zhou, Huali Long, Qinhua Chen, Jinjun Hou, Wanying Wu
Journal of Chromatography A.2024; 1736: 465406. CrossRef Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra
Cells.2024; 13(24): 2055. CrossRef Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials
Zijie Jin, Yan Yuan, Chen Zheng, Shijian Liu, Hongbo Weng
Journal of Diabetes and its Complications.2023; 37(8): 108558. CrossRef A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey
Stan Driessen, Vivian D. de Jong, Koen C. van Son, Tatiana Klompenhouwer, Yann Colardelle, Marco Alings, Cristophe Moreno, Stefan D. Anker, Manuel Castro Cabezas, Adriaan G. Holleboom, Diederick E. Grobbee, Maarten E. Tushuizen
United European Gastroenterology Journal.2023; 11(7): 654. CrossRef Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma
Rong Liu, Ming-Ping Qian, Ying-Yu Cui
Metabolism.2023; 147: 155665. CrossRef Iron depletion in “metabolic fatty liver syndromes”: a strong biological rationale with disappointing liver outcomes
Amedeo Lonardo
Exploration of Drug Science.2023; : 239. CrossRef Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
Chin-Hsiao Tseng
Cancers.2023; 15(17): 4276. CrossRef Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień
Medicina.2023; 59(10): 1789. CrossRef Extracellular Superoxide Dismutase Attenuates Hepatic Oxidative Stress in Nonalcoholic Fatty Liver Disease through the Adenosine Monophosphate-Activated Protein Kinase Activation
Heechul Nam, Ji Lim, Tae Kim, Eun Kim, Sae-Jong Oum, Si Bae, Cheol Park
Antioxidants.2023; 12(12): 2040. CrossRef Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
Young Chang, Soung Won Jeong, Jae Young Jang
Clinical and Molecular Hepatology.2023; 30(1): 129. CrossRef
|